Disease Landscape and Forecast 인사이트
종합적인 시장 정보와 실행 가능한 인사이트를 통해 장기적인 질병 전략을 최적화하세요.
Biomarkers in Oncology – Access & Reimbursement – Detailed, Expanded Analysis: Biomarkers in Oncology – Non-Small-Cell Lung Cancer, Breast Cancer, and Colorectal Cancer (US)
Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…
Biosimilars | Market Events and Forecast Landscape – Overview of Biosimilar Forecasts | 2023
In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…
Biosimilars | Market Events and Forecast Landscape – Forecast Methodology and General Market Assumptions | 2023
In 2021, sales of branded biologics for oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology indications exceeded $130 billion in the major pharmaceutical markets under…
Metabolic Dysfunction-Associated Steatohepatitis – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key non-alcoholic steatohepatitis patient populations, covering 171…
Metabolic Dysfunction-Associated Steatohepatitis – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of NASH comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total NASH prevalent cases for each country, as…
